Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

Denys, Gerald A; Callister, Steven M; Dowzicky, Michael J

doi:10.1186/1476-0711-12-24

Annals of Clinical Microbiology and Antimicrobials

Table 2 Antimicrobial susceptibility for Acinetobacter baumannii and multidrug-resistant (MDR) A. baumannii

From: Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

		Pacific	Mountain	West North Central	East North Central	Middle Atlantic	New England	South Atlantic	East South Central	West South Central	USA
*Acinetobacter baumannii*		N = 103	N = 72	N = 332	N = 694	N = 721	N = 77	N = 562	N = 162	N = 177	N = 2900
Amikacin	MIC ₅₀	4	4	4	8	4	4	4	4	4	4
	MIC ₉₀	≥128	≥128	≥128	≥128	64	8	64	≥128	≥128	≥128
	%S	71.8	69.4	80.4	58.8	78.1	100	85.1	69.8	71.2	74.3
Carbapenems	MIC ₅₀	1	1	1	4	1	1	1	2	1	1
	MIC ₉₀	16	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32
	%S	76.7	69.4	74.7	50.3	70.3	74.0	74.0	66.7	80.2	67.4
Cefepime	MIC ₅₀	16	8	8	16	16	16	8	32	8	16
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	46.6	55.6	55.7	38.2	42.7	48.1	52.8	40.1	55.9	46.3
Ceftazidime	MIC ₅₀	16	≤8	≤8	≥64	32	16	16	≥64	≤8	32
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	48.5	55.6	52.4	35.6	43.8	45.5	49.6	37.0	57.6	44.9
Ceftriaxone	MIC ₅₀	32	16	16	64	32	32	32	≥128	16	32
	MIC ₉₀	≥128	≥128	≥128	≥128	≥128	≥128	≥128	≥128	≥128	≥128
	%S	30.1	30.6	35.8	19.3	25.8	22.1	27.0	20.4	31.6	25.9
Levofloxacin	MIC ₅₀	0.5	0.25	0.25	8	8	4	2	8	1	4
	MIC ₉₀	≥16	≥16	≥16	≥16	≥16	≥16	≥16	≥16	≥16	≥16
	%S	55.3	62.5	56.9	33.1	40.5	46.8	51.1	35.8	53.7	44.4
Minocycline	MIC ₅₀	≤0.5	≤0.5	≤0.5	1	≤0.5	1	1	2	≤0.5	≤0.5
	MIC ₉₀	4	8	8	8	8	4	8	8	8	8
	%S	91.3	80.6	87.3	80.5	88.2	97.4	81.5	68.5	88.7	84.1
Pip-taz	MIC ₅₀	16	8	4	128	16	8	16	64	16	16
	MIC ₉₀	≥256	≥256	≥256	≥256	≥256	≥256	≥256	≥256	≥256	≥256
	%S	53.4	56.9	59.9	36.5	53.8	61.0	54.4	43.8	59.3	50.5
Tigecycline	MIC ₅₀	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
	MIC ₉₀	1	1	1	2	2	1	2	1	2	2
	%S	--	--	--	--	--	--	--	--	--	--
MDR *Acinetobacter baumannii*		N = 28	N = 23	N = 72	N = 326	N = 206	N = 13	N = 124	N = 50	N = 41	N = 883
Amikacin	MIC ₅₀	≥128	≥128	64	≥128	32	4	32	≥128	64	64
	MIC ₉₀	≥128	≥128	≥128	≥128	≥128	8	≥128	≥128	≥128	≥128
	%S	10.7	8.7	36.1	16.0	42.2	100	40.3	6.0	12.2	27.3
Carbapenems	MIC ₅₀	16	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32
	MIC ₉₀	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32
	%S	21.4	8.7	15.3	4.6	12.1	0.0	1.6	10.0	26.8	8.7
Cefepime	MIC ₅₀	≥64	≥64	≥64	≥64	≥64	32	32	≥64	32	≥64
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	0.0	4.3	4.2	10.4	2.4	0.0	5.6	2.0	2.4	5.9
Ceftazidime	MIC ₅₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	3.6	4.3	1.4	9.2	3.4	0.0	4.0	2.0	0.0	5.2
Ceftriaxone	MIC ₅₀	≥128	≥128	≥128	≥128	≥128	≥128	≥128	≥128	≥128	≥128
	MIC ₉₀	≥128	≥128	≥128	≥128	≥128	≥128	≥128	≥128	≥128	≥128
	%S	3.6	0.0	0.0	0.9	0.5	0.0	0.8	0.0	0.0	0.7
Levofloxacin	MIC ₅₀	≥16	8	8	≥16	≥16	≥16	≥16	≥16	≥16	≥16
	MIC ₉₀	≥16	≥16	≥16	≥16	≥16	≥16	≥16	≥16	≥16	≥16
	%S	0.0	4.3	2.8	0.9	2.4	0.0	0.0	0.0	0.0	1.2
Minocycline	MIC ₅₀	1	4	4	2	2	2	4	4	4	2
	MIC ₉₀	8	8	16	8	16	4	8	8	8	8
	%S	82.1	56.5	69.4	77.9	72.3	92.3	65.3	54.0	68.3	72.1
Pip-taz	MIC ₅₀	≥256	≥256	≥256	≥256	128	128	≥256	≥256	≥256	≥256
	MIC ₉₀	≥256	≥256	≥256	≥256	≥256	≥256	≥256	≥256	≥256	≥256
	%S	3.6	4.3	8.3	3.1	10.7	15.4	3.2	2.0	2.4	5.4
Tigecycline	MIC ₅₀	1	1	1	1	1	1	1	1	1	1
	MIC ₉₀	2	1	2	2	2	4	2	2	2	2
	%S	--	--	--	--	--	--	--	--	--	--

Amoxicillin-clavulanate and ampicillin are not presented in this table as they are inactive against A. baumannii.
% S, % susceptible, pip-taz piperacillin-tazobactam, carbapenems = imipenem/meropenem.
-- No CLSI approved interpretive criteria availableData not presented when N < 10 isolates.

Back to article page

ISSN: 1476-0711

Contact us

Submission enquiries: journalsubmissions@springernature.com